ProfileGDS5678 / 1426841_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 91% 91% 92% 90% 91% 92% 92% 92% 92% 91% 92% 91% 92% 91% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.4390491
GSM967853U87-EV human glioblastoma xenograft - Control 27.4394991
GSM967854U87-EV human glioblastoma xenograft - Control 37.5940392
GSM967855U87-EV human glioblastoma xenograft - Control 47.3563790
GSM967856U87-EV human glioblastoma xenograft - Control 57.4250191
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.4932992
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.4131492
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.6933892
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.4744592
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.464491
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.5834692
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.5696591
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.5522892
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.4201891